Infection Prevention and Control
Stay informed on the latest news and developments in infection prevention and control. AHA provides valuable resources and support to help you maintain a safe and clean environment.
Centers for Disease Control and Prevention Director Robert Redfield said the agency is in the process of setting up a public tracker for novel coronavirus (COVID-19) tests, and it could be available this week.
The Centers for Disease Control and Prevention updated its guidance for evaluating and testing patients for novel coronavirus (COVID-19), and for assessing and managing health care personnel with potential exposure to patients with the virus.
America’s Health Insurance Plans said it is taking action to make sure plans cover COVID-19 diagnostic testing and reduce service barriers, such as prior-authorization and cost-sharing. AHIP also is encouraging the use of telehealth and at-home care to widen access.
The Centers for Disease Control and Prevention updated its guidance for risk assessment and public health management of health care personnel with potential exposure to patients with novel coronavirus (COVID-19).
The House passed an $8.3 billion funding package for novel coronavirus (COVID-19) preparedness and response.
Health care personnel may use certain N95 and other respirators approved for use in industrial settings during the novel coronavirus (COVID-19) outbreak under an emergency use authorization approved by the Food and Drug Administration.
Six people near the Kirkland area of Washington state have died from COVID-19 complications, local health officials announced. At least five had underlying health conditions, and at least four were from the same long-term care facility.
The Centers for Disease Control and Prevention issued updated guidance for health care professionals evaluating and reporting patients under investigation for the novel coronavirus (COVID-19).
The Centers for Disease Control and Prevention reported the first possible U.S. case of community-spread of novel coronavirus (COVID-19), in a patient in northern California with no known potential exposure through travel or another infected patient.
The Department of Health and Human Services is aware of 20 pharmaceutical products made or with a critical active ingredient solely sourced in China, but to date is not aware of any expected shortages, HHS Secretary Alex Azar told House appropriators.